Announced Mon, 17 Aug · 11:59 IST
Q1 FY27: Revenue up 21%, EBITDA margin guide raised to 23%
Mgmt Guided Margin ImprovementAnalyst Day Multiyear TargetsCfo Debt Reduction RoadmapOrder Pipeline DisclosedInvestor Communications View source PDFExplain this filing
IPCALAB · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Price reaction · full curve 14 horizons · vs prior close
+8.4%1-day move
₹1733.00
prior close
₹1847.00
base price
In-mkt
timing
5m10m15m30m1D2D3D4D5D7D15D1M2M3M
-0.4-0.3+0.5+0.2+8.4+10.0+9.6+10.7——————
Up moveDown movePending
AI summary
Ipca Labs Q1 FY27 revenue grew 21% to INR2,788 cr. Consolidated EBITDA margins expanded 449 bps to 22.88%. Management raised FY27 revenue guidance from 12-13% to 14-16% and EBITDA margin guidance from 22% to 23%. Medium-term target is 25-26% consolidated margins. US generics seen at 15-17% growth. Debt reduced to INR193 cr with zero working capital borrowings. Capex of INR700-800 cr planned. Biotech pipeline of 7 biosimilars, revenue expected from FY29-30.
Likely market impact
Positive: broad-based growth, margin expansion, upgraded guidance, debt reduction, and a strong biosimilar pipeline point to an improving earnings trajectory.